Patents for A61P 35 - Antineoplastic agents (221,099)
05/2007
05/02/2007CN1313159C Hab18G/CD147 molecule small segment interfering RNA medicine and application thereof
05/02/2007CN1313158C Method of promoting nucleic acid transfer
05/02/2007CN1313151C Preparation of high-performance noncellular vaccine and usage
05/02/2007CN1313150C Therapeutic agent for treating autoimmune diseases
05/02/2007CN1313149C Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
05/02/2007CN1313148C HSA-free formulations of interferon-Beta
05/02/2007CN1313146C Methods and compositions useful for inhibition of 'alpha'v'beta'5 mediated angiogenesis
05/02/2007CN1313145C Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use
05/02/2007CN1313107C Medicine for treating tumor
05/02/2007CN1313104C Anticancer medicine composition with synergistic bupleurum root and polymyxin
05/02/2007CN1313101C Chinese medicine for strengthening antitumour thorapeutic effect of glossy ganoderma spore oil
05/02/2007CN1313100C Antitumour Chinese medicine preparation
05/02/2007CN1313099C Carbon gas gel transfusion agent, its preparing method and its use
05/02/2007CN1313094C Use of ZD6474 in preparation of drug for treating cancer in human treated by ionising radiation
05/02/2007CN1313093C New application of berbamine as intracorporeal antitumor drug
05/02/2007CN1313091C Vitamin C composition
05/02/2007CN1313088C Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders
05/01/2007USRE39608 Substituted benzimidazoles and their use as PARP inhibitors
05/01/2007USRE39606 Synthetic libraries of random oligomers, each member comprising an oligomer linked to a microchip encoded with information identifying structure of oligomer, for drug screening
05/01/2007US7211680 (5Z,7E,22E)-(1S,3R,24R)-25-phenyl-26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol; treating hyperprolifierative diseases of the skin, tumor diseases and precancerous stages, auto-immune diseases, rejection reactions in the case of autologous, allogenic or xenogenic transplants, AIDS
05/01/2007US7211656 Using the enzymes to make polyunsaturated fatty acids; added to pharmaceutical compositions, nutritional compositions, animal feeds, cosmetics
05/01/2007US7211648 Gag-peptide complex
05/01/2007US7211600 Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
05/01/2007US7211598 Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
05/01/2007US7211597 Antiinflammatory agents; rheumatic diseases; anticancer agents
05/01/2007US7211590 Such as 2-(nitrooxy)ethyl-2-(((3-methyl-4-(2,2,2-trifluoro-ethoxy)-2 -pyridyl)methyl)sulfinyl)benzimidazolecarboxylate; kits; for treating gastrointestinal disorders/ulcers
05/01/2007US7211587 Administering compounds such as N-{3-Chloro-4-[(6,7-dimethoxy-4-quinolyl)-oxy]phenyl}-N'-(3-isoxazolyl)urea for therapy of malignant tumors
05/01/2007US7211586 Substituted tetrahydroisoquinolines
05/01/2007US7211583 Substituted azaindole as drugs and enzyme inhibitors
05/01/2007US7211578 Nitrogenous tetrahydropyridyl-alkyl-heterocycles with TNF activity
05/01/2007US7211575 Methods of treating cytokine mediated diseases
05/01/2007US7211570 Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes ("KHSV")
05/01/2007US7211563 For use in diagnosis, study, prophylaxis, and therapy of diseases and disorders related to body-weight regulation, metabolic diseases such as obesity, as well as related disorders such as adipositas, eating disorders, cachexia
05/01/2007US7211562 cytotoxic agents followed by a heat shock protein 90 inhibitor, has a synergistic effect on the growth inhibition of cells; destroying cells having a cell proliferative disorder with wild-type retinoblastoma gene
05/01/2007US7211424 Mammalian Subtilisin/kexin isozyme SKI-1: a proprotein convertase with a unique cleavage specificity
05/01/2007US7211411 Human papilloma virus treatment
05/01/2007US7211404 Liver engrafting cells, assays, and uses thereof
05/01/2007US7211398 Human genes and gene expression products: II
05/01/2007US7211387 DNA molecule encoding a variant paraoxonase and uses thereof
05/01/2007US7211276 Method for preventing ulceration or irritation of mucosa
05/01/2007US7211258 Protein A compositions and methods of use
05/01/2007US7211257 Methods for inducing apoptosis in ovarian carcinoma cells using an anti-regeneration and tolerance factor antibody
05/01/2007US7211252 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
05/01/2007US7211251 Antibodies to transferrin receptor-like proteins
05/01/2007US7211250 Method and composition for inhibiting cancer cell growth
05/01/2007US7211246 Compositions comprising oestrone-3-0-sulphamate and trail (TNF-related apoptosis inducing ligand)
05/01/2007CA2392917C Pin1 as a marker for abnormal cell growth
05/01/2007CA2366679C Stabilized oral pharmaceutical composition containing iodide and iodate and method
05/01/2007CA2320706C 20-hete antagonists and agonists
05/01/2007CA2301590C 2-aminopyridines as inhibitors of cyclooxygenase-2
05/01/2007CA2296036C Dolastatin 15 derivatives
05/01/2007CA2283587C Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with n- or c-linked imidazoles
05/01/2007CA2268434C Mycophenolic bisphosphonate derivatives and their preparation from tetraphosphonate bicyclic trisanhydrides
05/01/2007CA2227205C Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
05/01/2007CA2206748C Salts of ethyl 3-(2-(4-(4-(amino-imino-methyl)phenyl)-4-methyl-2,5-dioxoimidazolidin-1-yl)acetylamino)-3-phenylpropionate
05/01/2007CA2185394C Biotinderivate
05/01/2007CA2120303C Cyclic adhesion inhibitors
04/2007
04/26/2007WO2007048070A2 Pyrrolo-pyridine derivatives for the treatment of cancer diseases
04/26/2007WO2007047315A1 Amifostine dihydrate crystalline composition
04/26/2007WO2007046729A1 Method of acting upon organism by targeted delivery of biologicaly active substances into m itochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose
04/26/2007WO2007046524A1 EXTRACT LIQUID CONTAINING β-CRYPTOXANTHIN INGREDIENT, AND FOOD OR BEVERAGE AND SOAP OR COSMETIC EACH CONTAINING THE EXTRACT LIQUID
04/26/2007WO2007046456A1 Agent for preventing or treating pancreas cancer, ovary cancer or liver cancer containing novel water-soluble prodrug
04/26/2007WO2007046392A1 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
04/26/2007WO2007045844A1 Benzamide compounds useful as histone deacetylase inhibitors
04/26/2007WO2007045758A1 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
04/26/2007WO2007045389A2 Method for discovering inhibitors of the epstein-barr virus-induced gene 3 (ebi3) and derivatives thereof for the treatment of metastasizing tumors and allergic asthma
04/26/2007WO2007045096A1 Oligoheteroaromatic luminiscent assemblies as high-affinity dna sequence-directed ligands
04/26/2007WO2007045027A1 Reduction of side effects from aromatase inhibitors used for treating breast cancer
04/26/2007WO2007023382A3 Pyrimidine amino pyrazole compounds, potent kinase inhibitors
04/26/2007WO2007022813A3 A METHOD FOR PREPARING A STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES OF TNFα AND A CARRIER PROTEIN
04/26/2007WO2007020277A3 Condensed pyrimidine derivatives as inhibitors of foic acid-dependent enzymes
04/26/2007WO2007014839A3 Cathepsin k inhibitors
04/26/2007WO2007004060A3 Cytokine receptor modulators and uses thereof
04/26/2007WO2007001839A3 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
04/26/2007WO2006136606A3 Oxindole derivatives
04/26/2007WO2006131833A3 New hybrid oligomers. their preparation process and pharmaceutical compositions containing them
04/26/2007WO2006125815A3 Tetrahydropyridothiophenes for use in the treatment of cancer
04/26/2007WO2006125139A3 Therapeutic uses of kallikreins
04/26/2007WO2006074451A9 Targeted chimeric molecules for cancer therapy
04/26/2007WO2006053121A3 Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
04/26/2007WO2006050930A3 Conjugates with enhanced cell uptake activity
04/26/2007WO2006042724A3 Magnetic particles for therapy and diagnosis
04/26/2007WO2006040569A8 Thiophene amide compounds for use in the treatment or prophylaxis of cancers
04/26/2007WO2005115991A8 Anti-cytokine heterocyclic compounds
04/26/2007WO2004069139A3 4-aminopyrimidin-5-yl-methanone derivatives for inhibition of cdk4 activity
04/26/2007US20070093658 used for the treatment of a cancer in mammals; anticarnogenic or antitumor agents
04/26/2007US20070093553 HMB compositions and uses thereof
04/26/2007US20070093532 Benzimidazole carboxamides as raf kinase inhibitors
04/26/2007US20070093512 4-Phenylaminopyrido[4,3-d]pyrimidines 6-heteroaryl-substituted, in which the heteroaryl is substituted with a sulfonylethylamino-, thio- or oxy- group; protein tyrosine kinase inhibitors, used especially to treat various malignancies
04/26/2007US20070093506 Inhibitors of tyrosine kinases
04/26/2007US20070093482 Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors
04/26/2007US20070093480 e.g. 2 {5,6-dimethoxy-1-[2-(4-methylpiperazin- 1 -yl)ethyl]-1H-indol-3 -yl}-1H-pyrrolo[2,3- b]pyridine; Insulin Growth Factor-1 (somatomedin) antagonist; antiproliferative, antitumor agent; solid tumor; prostate, lung and breast cancer
04/26/2007US20070093479 6-chloro-N-(3,3-dimethylbutyl)-5-phenyl-1H-indazol-3-amine; for treating neurodegenerative diseases such as Alzheimer's, fronto-parietal dementia, Pick's disease, Parkinson's disease, type II diabetes, corticobasal degeneration, in which phosphorylation of the tau protein is observed
04/26/2007US20070093472 1-[(4-Ethynylphenyl)]-2-[(phenyl)]-pyrrolidine-1,2-dicarboxamide derivatives as inhibitors of coagulation factors xa and viia for the treatment of thromboses
04/26/2007US20070093445 RNA interference mediating small RNA molecules
04/26/2007US20070093441 useful to efficiently induce self-specific immune responses; comprising a virus-like particle and at least one protein, or peptide of IL-5, IL-13 and/or eotaxin
04/26/2007US20070093435 Modulation of cell phenotype by inhibitory rna
04/26/2007US20070093434 Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
04/26/2007US20070093422 Drug comprising synthetic peptide analogs for the treatment of cancer
04/26/2007US20070093419 Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent